Anika Therapeutics (ANIK) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.45 --0%
EPS Growth %: +950.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +950.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.37, $0.01 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $23.89 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
